NCT06649695

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: European Myeloma Network B.V. · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Conditions

• AL Amyloidosis

Interventions

Type	Name	Description
DRUG	Teclistamab	Teclistamab will be administered via a subcutaneous injection (SC)

Timeline

• Start date: 2025-07-02
• Primary completion: 2028-09-01
• Completion: 2028-09-01
• First posted: 2024-10-21
• Last updated: 2025-09-25

Locations

10 sites across 6 countries: Australia, France, Germany, Greece, Italy, Netherlands

Regulatory

• FDA-regulated drug study